| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3294551 | Gastroenterology | 2012 | 12 Pages |
Abstract
Adalimumab was safe and more effective than placebo in inducing and maintaining clinical remission in patients with moderate-to-severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressants.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
William J. Sandborn, Gert van Assche, Walter Reinisch, Jean-Frederic Colombel, Geert D'Haens, Douglas C. Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal B. Thakkar,